Bisphosphonate IV·Endocrinology - Thyroid & Bone

Zoledronic acid

Osteoporosis, Paget's disease, Hypercalcemia of malignancy, prevention of skeletal-related events in bone metastases

Authority requiredPBSBISPHOSPHONATE IVAclasta (5 mg - Osteo), Zometa (4 mg - Oncology)5 mg+2

No source link confirmed for this record yet. Its own source notes are under Additional.

At a glance

Max Dose

5 mg/year

Caution: Half-life

10 YEARS

Caution: Flu-Like

1ST DOSE SEVERE

High risk: Hypocalcemia

CRITICAL RISK

Cautions

Avoid / Cautions

Hypocalcemia, severe renal impairment (eGFR < 35). Pregnancy Category B3.

Where it stands

Rapid Summary

Overview

Ultra-potent, intravenous bisphosphonate. A single 15-minute infusion provides a full year of osteoporosis protection. Completely bypasses the severe GI side effects of oral bisphosphonates.

Clinical Focus

The patient MUST have normal Vitamin D and Calcium levels before the infusion, or it will trigger a lethal hypocalcemic crash.

Bottom Line

Zoledronic acid is a once-yearly IV bisphosphonate for osteoporosis providing maximum adherence, but causes acute-phase reaction (flu-like symptoms) after first infusion and requires adequate renal function.

Formulation & Access

Brand Names

Aclasta (5 mg - Osteo), Zometa (4 mg - Oncology)

Parenteral

Vials (4 mg/5 mL, 5 mg/100 mL) for IV infusion.

Prescribing & PBS

Authority Required (PBS). Administered in hospital or infusion clinics.

Indications & Use

Primary

PBSTGA

Osteoporosis, Paget's disease, Hypercalcemia of malignancy, prevention of skeletal-related events in bone metastases.

Clinical Place

The definitive option for patients who cannot tolerate oral bisphosphonates due to reflux/esophagitis, or those who are non-compliant.

Quick reference

Class & Role

Bisphosphonate IV — Ultra-potent, intravenous bisphosphonate.

Route / Formulation

Vials (4 mg/5 mL, 5 mg/100 mL) for IV infusion. (Aclasta (5 mg - Osteo), Zometa (4 mg - Oncology))

Usual Dose & Max

IV 5 mg infused strictly over no less than 15 minutes, ONCE YEARLY. Max 5 mg ONCE YEARLY (Osteoporosis) or 4 mg q3-4 weeks (Oncology/Bone Mets).

Key Indication Doses

Osteoporosis: IV 5 mg infused strictly over no less than 15 minutes, ONCE YEARLY. Hypercalcemia of Malignancy: IV 4 mg STAT. Renal Impairment: Do not use if eGFR < 35. Rapid infusion causes acute renal failure. Ensure patient is highly hydrated.

Best Uses

Key Risks

Immunological: 'Acute Phase Reaction'. Within 24-48 hours of the *first* infusion, up to 50% of patients develop a severe flu-like syndrome (high fever, bone pain, rigors). It is harmless but terrifying. Prevent with Paracetamol. Metabolic: Severe, symptomatic hypocalcemia (tetany/seizures) if given to a Vitamin D deficient patient. Musculoskeletal: Osteonecrosis of the jaw (ONJ) - risk is much higher with IV formulations than oral.

Key Interactions

Loop diuretics and Aminoglycosides massively compound the risk of nephrotoxicity and hypocalcemia.

Monitoring

You MUST hold a recent blood test proving normal Calcium, Vitamin D, and eGFR in your hand before authorizing the infusion. Ensure the patient drinks 2 glasses of water before the infusion to protect the kidneys.

Clinical Pearl

A single 15-minute infusion of 5mg Zoledronic Acid reduces the risk of spinal fractures by 70% over the next 3 years. It is an incredibly powerful, low-compliance-burden therapy.

Access

Authority requiredAclasta (5 mg - Osteo), Zometa (4 mg - Oncology)

Brand: Aclasta (5 mg - Osteo), Zometa (4 mg - Oncology)
PBS status: Authority required

From this page

No calculator, monitoring schedule or factsheet is linked to this medicine page yet.